Circio partners with Solid Biosciences to evaluate gene therapy for genetic heart disease
SLDB•Circio and Solid Biosciences will evaluate combining Circio’s generation 5 circVec constructs with Solid’s POLARIS-101 AAV capsid for gene therapies targeting genetic heart disease. Generation 5 circVec has demonstrated up to 200-fold enhanced gene expression from AAV vectors in the heart in vivo.
